Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma

Fig. 3

LMP1 upregulated PD-L1 expression through MAPK/NF-κB pathway in NK92 cells. a The expression level of p-Raf-B, Raf-B, p-p38, p38, p-JNK, JNK, p-ERK, ERK, and p65 in LMP1-expressing NK92 (LMP1) and negative control NK92 (NC) cell lines. b The expression level of p-Raf-B, Raf-B, p-p38, p38, p-JNK, JNK, p-ERK, ERK, p65, and PD-L1 in negative control NK92 (NC) or LMP1-expressing NK92 (LMP1) cell line treated with 0.1 μM SB590885, a selective B-Raf inhibitor for 1 h. c The expression level of p-ERK, ERK, p65, and PD-L1 in negative control NK92 (NC) or LMP1-expressing NK92 (LMP1) cell line treated with 20 μM PD98059, a selective ERK inhibitor for 1 h. d The expression level of p-p38, p38, p65, and PD-L1 in negative control NK92 (NC) or LMP1-expressing NK92 (LMP1) cell line treated with 10 μM SB203580, a selective p38 inhibitor for 1 h. e The expression level of p-JNK, JNK, p65, and PD-L1 in negative control NK92 (NC) or LMP1-expressing NK92 (LMP1) cell line treated with 20 μM SP600125, a selective JNK inhibitor for 1 h. f The expression level of p65 and PD-L1 in negative control NK92 (NC) or LMP1-expressing NK92 (LMP1) cell line treated with 100 μM pyrrolidine dithiocarbamate (PDTC), a selective inhibitor of NF-κB for 1 h

Back to article page